JMP Securities restated their market outperform rating on shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) in a research note released on Monday morning, Benzinga reports. JMP Securities currently has a $17.00 price target on the stock.
A number of other equities research analysts also recently weighed in on the company. LADENBURG THALM/SH SH raised Acrivon Therapeutics from a neutral rating to a buy rating and set a $16.00 price target for the company in a research note on Monday. HC Wainwright reissued a buy rating and issued a $22.00 price objective on shares of Acrivon Therapeutics in a research note on Monday. Piper Sandler Companies reissued a buy rating and issued a $30.00 price objective on shares of Acrivon Therapeutics in a research note on Friday, September 6th. Finally, BMO Capital Markets reissued an outperform rating and issued a $28.00 price objective (up from $25.00) on shares of Acrivon Therapeutics in a research note on Monday. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Acrivon Therapeutics has an average rating of Buy and a consensus price target of $23.86.
Get Our Latest Stock Report on Acrivon Therapeutics
Acrivon Therapeutics Price Performance
Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.08. On average, equities research analysts expect that Acrivon Therapeutics will post -2.4 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in ACRV. Perceptive Advisors LLC increased its stake in Acrivon Therapeutics by 78.2% in the second quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company’s stock valued at $31,093,000 after acquiring an additional 2,353,000 shares during the period. Sands Capital Ventures LLC grew its stake in shares of Acrivon Therapeutics by 28.4% in the 2nd quarter. Sands Capital Ventures LLC now owns 2,122,605 shares of the company’s stock valued at $12,311,000 after purchasing an additional 470,000 shares during the period. Marshall Wace LLP raised its holdings in shares of Acrivon Therapeutics by 58.8% in the 2nd quarter. Marshall Wace LLP now owns 948,866 shares of the company’s stock worth $5,503,000 after buying an additional 351,397 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Acrivon Therapeutics by 6.6% in the 1st quarter. Vanguard Group Inc. now owns 507,185 shares of the company’s stock worth $3,626,000 after buying an additional 31,208 shares in the last quarter. Finally, Baker BROS. Advisors LP bought a new position in shares of Acrivon Therapeutics during the 1st quarter worth approximately $378,000. 71.62% of the stock is owned by institutional investors.
Acrivon Therapeutics Company Profile
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
See Also
- Five stocks we like better than Acrivon Therapeutics
- Consumer Discretionary Stocks Explained
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Best Stocks Under $5.00
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.